ABI-007: APPX completed enrollment of 2 Phase II trials of ABI-007 as a monotherapy at 2 different doses (175 mg/m2 and 300 mg/m2) in metastatic breast cancer p

American Pharmaceutical Partners Inc. (APPX), Los Angeles, Calif. Product: ABI-007 Business: Cancer Therapeutic category: Cytotoxic Target: Microtubules Description: Albumen stabilized nanoparticle f...